RGNX has been the subject of several other research reports. Raymond James began coverage on Adverum Biotechnologies in a research note on Thursday, June 13th. They set a market perform rating for the company. TheStreet cut Trade Desk from a b- rating to a c- rating in a research note on Thursday, May 9th. Zacks Investment Research cut Zynerba Pharmaceuticals from a buy rating to a hold rating in a research note on Saturday, May 11th. ValuEngine cut Yext from a strong-buy rating to a buy rating in a research note on Friday, May 10th. Finally, Chardan Capital reaffirmed a buy rating and issued a $150.00 price objective (up from $145.00) on shares of Regenxbio in a research note on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $81.53.
RGNX stock opened at $47.48 on Thursday. The stock’s fifty day simple moving average is $48.19. The company has a quick ratio of 14.21, a current ratio of 14.21 and a debt-to-equity ratio of 0.01. Regenxbio has a 52-week low of $38.56 and a 52-week high of $83.45.
Regenxbio (NASDAQ:RGNX) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04). The business had revenue of $0.88 million for the quarter. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. As a group, equities research analysts anticipate that Regenxbio will post -2.46 earnings per share for the current fiscal year.
In other news, SVP Curran Simpson sold 18,000 shares of Regenxbio stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $900,000.00. Following the completion of the sale, the senior vice president now directly owns 57,500 shares of the company’s stock, valued at $2,875,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Olivier Danos sold 2,000 shares of Regenxbio stock in a transaction on Monday, April 15th. The shares were sold at an average price of $52.66, for a total value of $105,320.00. Following the completion of the sale, the insider now directly owns 8,500 shares of the company’s stock, valued at $447,610. The disclosure for this sale can be found here. Insiders sold 75,000 shares of company stock valued at $3,725,970 over the last ninety days. Insiders own 13.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of RGNX. Berman Capital Advisors LLC purchased a new position in Regenxbio in the fourth quarter valued at $33,000. NumerixS Investment Technologies Inc purchased a new position in Regenxbio in the fourth quarter valued at $50,000. Mckinley Capital Management LLC Delaware boosted its holdings in Regenxbio by 51.8% in the first quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 303 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Regenxbio in the first quarter valued at $55,000. Finally, SG3 Management LLC purchased a new position in Regenxbio in the first quarter valued at $115,000. 81.48% of the stock is owned by institutional investors and hedge funds.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.